BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19509468)

  • 1. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.
    Kren BT; Unger GM; Sjeklocha L; Trossen AA; Korman V; Diethelm-Okita BM; Reding MT; Steer CJ
    J Clin Invest; 2009 Jul; 119(7):2086-99. PubMed ID: 19509468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
    Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
    Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
    Liu L; Mah C; Fletcher BS
    Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII can be synthesized in hemophilia A mice liver by bone marrow progenitor cell-derived hepatocytes and sinusoidal endothelial cells.
    Yadav N; Kanjirakkuzhiyil S; Ramakrishnan M; Das TK; Mukhopadhyay A
    Stem Cells Dev; 2012 Jan; 21(1):110-20. PubMed ID: 21480781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice.
    Kumaran V; Benten D; Follenzi A; Joseph B; Sarkar R; Gupta S
    J Thromb Haemost; 2005 Sep; 3(9):2022-31. PubMed ID: 16102109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasound-mediated gene delivery specifically targets liver sinusoidal endothelial cells for sustained FVIII expression in hemophilia A mice.
    Lawton SM; Manson MA; Fan MN; Chao TY; Chen CY; Kim P; Campbell C; Cai X; Vander Kooi A; Miao CH
    Mol Ther; 2024 Apr; 32(4):969-981. PubMed ID: 38341614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
    Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.
    Lipshutz GS; Sarkar R; Flebbe-Rehwaldt L; Kazazian H; Gaensler KM
    Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13324-9. PubMed ID: 10557319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
    Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
    Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
    Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
    PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
    Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A.
    Zanolini D; Merlin S; Feola M; Ranaldo G; Amoruso A; Gaidano G; Zaffaroni M; Ferrero A; Brunelleschi S; Valente G; Gupta S; Prat M; Follenzi A
    Haematologica; 2015 Jul; 100(7):881-92. PubMed ID: 25911555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
    VandenDriessche T; Vanslembrouck V; Goovaerts I; Zwinnen H; Vanderhaeghen ML; Collen D; Chuah MK
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10379-84. PubMed ID: 10468616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
    Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
    Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
    Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB
    Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
    Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
    Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.